MBQIF (MindBio Therapeutics) Net Margin %: 0.00% (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

MBQIF MindBio Therapeutics Corp MBQIF
10 GF Score
Price $0.15
! 1 Warning Sign
View Full Analysis

What is MindBio Therapeutics Net Margin %?

MindBio Therapeutics MBQIF -11.26% 10 Net Margin % is 0.00% as of Mar. 2026. GuruFocus rates MBQIF with a GF Score™ of 10/100. The stock has 1 warning sign investors should review. Among 944 Biotechnology companies, MindBio Therapeutics ranks worse than 105932.1% on this metric.

Net margin is calculated as Net Income divided by its Revenue. MindBio Therapeutics's Net Income for the three months ended in Mar. 2026 was $-2.06 Mil. MindBio Therapeutics's Revenue for the three months ended in Mar. 2026 was $0.00 Mil. Therefore, MindBio Therapeutics's net margin for the quarter that ended in Mar. 2026 was 0.00%.

The historical rank and industry rank for MindBio Therapeutics's Net Margin % or its related term are showing as below:


MBQIF's Net Margin % is not ranked *
in the Biotechnology industry.
Industry Median: -78.87
* Ranked among companies with meaningful Net Margin % only.

MindBio Therapeutics  (OTCPK:MBQIF) Net Margin % Explanation

Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.

But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.

MindBio Therapeutics Net Margin % Related Terms

MindBio Therapeutics Net Margin % Historical Data

* Premium members only.

The historical data trend for MindBio Therapeutics's Net Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

MindBio Therapeutics Net Margin % Chart

MindBio Therapeutics Annual Data
Trend Jun21 Jun22 Jun23 Jun24 Jun25
Net Margin %
0.00 0.00 0.00 0.00 0.00

MindBio Therapeutics Quarterly Data
Jun21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Net Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

MBQIF vs : Net Margin % Comparison

For the Biotechnology subindustry, MindBio Therapeutics's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

MindBio Therapeutics Net Margin % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, MindBio Therapeutics's Net Margin % distribution charts can be found below:

* The bar in red indicates where MindBio Therapeutics's Net Margin % falls into.


MBQIF
10GF Score
MindBio Therapeutics Corp MBQIF
Net Margin % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

MindBio Therapeutics Net Margin % Calculation

Net margin - also known as net profit margin is the ratio of Net Income divided by net sales or Revenue, usually presented in percent.

MindBio Therapeutics's Net Margin for the fiscal year that ended in Jun. 2025 is calculated as

Net Margin=Net Income (A: Jun. 2025 )/Revenue (A: Jun. 2025 )
=-2.807/0
= %

MindBio Therapeutics's Net Margin for the quarter that ended in Mar. 2026 is calculated as

Net Margin=Net Income (Q: Mar. 2026 )/Revenue (Q: Mar. 2026 )
=-2.058/0
= %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Net Margin % →
What does a Net Margin % of 0.00% mean?
MindBio Therapeutics (MBQIF) has a Net Margin % of 0.00% as of Mar. 2026. Net margin is the ratio of total net income to net sales. View historical data on MindBio Therapeutics and its competitors. According to the industry distribution chart, MindBio Therapeutics ranks #999999 out of 944 companies in the Biotechnology industry.
Is MindBio Therapeutics' Net Margin % too high?
MindBio Therapeutics' current Net Margin % is 0.00%. Based on the distribution chart, MindBio Therapeutics ranks #999999 out of 944 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, MindBio Therapeutics has a GF Score™ of 10/100, reflecting its overall financial health beyond just this single metric.
How does MindBio Therapeutics' Net Margin % compare to ?
According to the Biotechnology industry distribution chart, MindBio Therapeutics ranks #999999 out of 944 companies for Net Margin %. This places MindBio Therapeutics in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Margin % for a Biotechnology company?
A good Net Margin % depends on the Biotechnology industry context. However, Net Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Margin % mean?
A high Net Margin % can signal that a stock is expensive relative to its fundamentals. Net margin is the ratio of total net income to net sales. View historical data on MindBio Therapeutics and its competitors. MindBio Therapeutics's current Net Margin % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is MindBio Therapeutics stock overvalued right now?
MindBio Therapeutics (MBQIF) has a current Net Margin % of 0.00%. The current Net Margin % is 0.00%. MindBio Therapeutics' overall GF Score™ is 10/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Margin % calculated?
Net Margin % is calculated from a company's financial statements. For MindBio Therapeutics (MBQIF), the current Net Margin % is 0.00% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

MindBio Therapeutics Business Description

Comparable Companies
Other Exchanges WF60:GermanyMBIO:Canada
Address 91-97 William Steet, Level 4, Melbourne, VIC, AUS, 3000
MindBio Therapeutics Corp is engaged in the research, development, and testing of psychedelic substances as a potential treatment for the management of a broad range of mental health conditions. The company invests in clinical research to discover potential new treatment options and aims to create novel medicines and treatment regimes from breakthrough microdosing studies. Geographically, the company's activities take place in Australia.
10GF Score

Get the complete analysis for MBQIF

Net Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.15
Price